MedPath

MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases

Not Applicable
Recruiting
Conditions
Brain Metastases
Interventions
Other: MRI
Registration Number
NCT04246879
Lead Sponsor
Duke University
Brief Summary

The purpose of this study is to test whether an additional magnetic resonance image (MRI) sequence can improve the ability to distinguish radiation damage from tumor recurrence in participants with brain metastasis who have previously been treated with stereotactic radiosurgery (SRS).

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
37
Inclusion Criteria
  • Adult patients, age ≥18
  • Metastatic malignancy with at least 1 brain metastasis previously treated with SRS
  • Patients may have also received whole brain radiation therapy (WBRT) for management of brain metastatic disease but this is not required for study participation
  • Patients must have been diagnosed with a metastatic solid tumor of any histological type except small cell lung cancer (SCLC), or lymphoma.
  • Radiographic progression on post-SRS imaging at previously treated SRS site(s)
  • Must be a candidate for brain surgery as determined by treating neurosurgeon and/or anesthesia team
  • Patients must sign study-specific informed consent prior to study entry
Read More
Exclusion Criteria
  • Poor surgical candidate as determined by treating neurosurgeon and/or anesthesia team
  • Unable to undergo contrasted MRI (e.g. incompatible medical device, inadequate renal function per standard institutional clinical protocol, contrast allergy)
  • Small cell lung cancer (SCLC) or lymphoma histology
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
MRIMRI-
Primary Outcome Measures
NameTimeMethod
number of positive MRI sequences along with positive tumor biopsiesbaseline

true tumor will be detected by delayed MRI as determined by biopsy

number of negative MRI sequences along with negative tumor biopsiesbaseline

absence of tumor will be detected by delayed MRI as determined by biopsy

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Duke University Health System

🇺🇸

Durham, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath